Every manufacturer quotes a monthly output figure. Far fewer can show you the eight weeks of native production data behind it.
For overseas distributors sourcing advanced wound care dressings, the gap between claimed capacity and delivered capacity is where supply contracts break down. A “10 million units per month” headline tells you nothing about whether that output survives a raw-material disruption, a planned maintenance window, or a sudden demand spike from a new hospital tender.
This checklist gives you a structured framework to verify real, repeatable production capacity — not the marketing version of it. It covers three pillars: OEE (how efficiently the line actually runs), uptime and maintenance discipline (what happens when equipment is planned or unplanned down), and redundancy (what the fallback looks like when the primary path fails). A worked reference from SLK Medical’s capacity matrix is included to show what verified documentation looks like in practice.
Key Takeaway: Claimed capacity and demonstrated capacity are different measurements. This checklist helps you collect the evidence that distinguishes one from the other before you commit supply volumes.
Why Marketing Claims Are Not a Capacity Benchmark
Manufacturers publish rated capacity — the theoretical maximum under ideal, uninterrupted conditions. That number is useful as a ceiling. It is not a planning figure.
What you need for distribution planning is sustained actual capacity: the output the plant has repeatedly achieved over recent weeks after accounting for downtime, changeovers, maintenance windows, scrap, and rework. According to NetSuite’s manufacturing capacity analysis guide, the gap between design capacity and effective capacity is almost always larger than suppliers disclose upfront, and identifying the bottleneck — the single constrained step that limits the entire line — is the first task in any serious capacity review.
For medical-grade products manufactured under ISO 13485 quality management systems, the challenge is compounded. Validation runs, cleanroom-compliance holds, and regulatory change-control processes all consume time that rated-capacity numbers typically exclude.
The production capacity assessment checklist below is structured in five sections. Work through each section with the supplier before signing volume commitments.
Section 1: Baseline Output and OEE Verification
OEE — Overall Equipment Effectiveness — is the standard composite metric for manufacturing productivity. It is calculated as Availability × Performance × Quality, expressed as a percentage. A line running at 90% availability, 95% performance, and 99% quality produces an OEE of approximately 85%.
According to the 2025 OEE benchmarks published by Godlan, medical device manufacturers average 78.2% OEE, the highest average across nine discrete manufacturing sectors. Top-quartile performers exceed 85%. Below 65% signals significant reliability risk.
Checklist Item | Evidence to Request | Pass / Fail |
|---|---|---|
☐ Supplier has shared last 8–12 weeks of native output data (not marketing summaries) | Hourly/daily production logs, planned vs. actual output by line | |
☐ OEE is broken into its three components: Availability, Performance, Quality | OEE dashboard or line-level calculation with component breakdown | |
☐ “Uptime” definition is clarified and consistent | Written definition confirming whether uptime = machine running time, scheduled production time, or sellable-output time | |
☐ Claimed monthly output matches the bottleneck constraint, not rated capacity | Capacity analysis showing design capacity and effective capacity at each critical step | |
☐ Scrap, rework, and first-pass yield trends are available for the last 12 weeks | Quality data by batch or lot, scrap Pareto | |
☐ OEE or yield data is separated by SKU family (e.g., bordered vs. non-bordered dressing configurations) | SKU-level throughput report |
Pro Tip: Ask for raw shift logs rather than summarized reports. Summaries can blend planned shutdown time into “uptime” in ways that inflate the number. Raw logs show every stop event individually.
Section 2: Uptime Definition and Maintenance Discipline
Uptime without maintenance context is a vanity metric. What you need to know is why the line goes down, how long it stays down, and whether the downtime pattern is shrinking or growing.
Mean Time Between Failures (MTBF) and Mean Time to Repair (MTTR) are the two operational signals that answer those questions. A plant with high MTBF and low MTTR has systematic maintenance control. A plant with frequent, short outages — common in facilities that have traded preventive maintenance for reactive repair — often reports high uptime numbers while masking chronic reliability erosion.
Checklist Item | Evidence to Request | Pass / Fail |
|---|---|---|
☐ Preventive maintenance schedules are documented and current | PM schedule with completion records for the last 6 months | |
☐ MTBF and MTTR are tracked per critical asset | Asset-level maintenance KPI report | |
☐ Critical spare parts are stocked on-site | Spare-parts inventory list for high-wear / long-lead-time components | |
☐ Planned downtime (PM, changeovers, cleaning validation) is clearly separated from unplanned downtime in records | Downtime log with classification codes: planned vs. unplanned, reason code | |
☐ Unplanned downtime has been trending flat or declining over the past 6 months | Downtime trend chart | |
☐ Staffing for maintenance is defined and not person-dependent | Maintenance team structure; cross-training records; shift coverage plan |
For medical manufacturing environments, cleaning validation and equipment re-qualification events count as planned downtime and must be factored into the sustainable output calculation. A facility running 20-shift weeks that uses two of those shifts for equipment cleaning and validation is effectively a 18-shift plant for planning purposes.
Section 3: Redundancy — Equipment, Utilities, and Supply Chain
Redundancy is the capacity that exists after a primary path fails. It is not a luxury feature. For distributors managing hospital tender commitments, the question is not whether disruption will happen — it is whether the supplier can absorb it without cascading into your supply chain.
There are three levels of redundancy worth evaluating: equipment redundancy (duplicate or backup production assets), utility redundancy (power, air, water, HVAC, sterilization), and supply-chain redundancy (dual sourcing of critical raw materials).
Checklist Item | Evidence to Request | Pass / Fail |
|---|---|---|
☐ Critical production equipment has a redundant unit or validated backup process | Equipment list with redundancy notation; documented alternate work-cell procedure | |
☐ Utility systems (power, compressed air, HVAC) have N+1 backup provision | Facility utility diagram; generator and UPS test records | |
☐ Sterilization capacity (EO or gamma) is not single-sourced | Sterilization partner list; contract terms for backup sterilization | |
☐ Dual sourcing exists for polyurethane foam and silicone adhesive systems — the two highest-criticality raw materials in silicone foam dressing production | Approved supplier list showing ≥2 qualified sources for each critical material | |
☐ Safety stock policy is defined and measured (minimum weeks on hand for finished goods and key raw materials) | Safety stock targets and current inventory position | |
☐ Business continuity plan exists and has been tested or reviewed in the past 24 months | Business continuity document with review date | |
☐ Supplier has geographic manufacturing redundancy or a credible secondary facility plan | Facility location data; expansion roadmap where applicable |
Key Takeaway: Single-source dependency on a raw material or a sterilization partner is a supply risk, not just a cost issue. Verify the approved supplier list directly — do not accept a verbal confirmation.
Section 4: Process Capability and Quality-System Controls
Capacity that cannot sustain quality output is not useful capacity. A line running at 10 million units per month with a 5% rework rate is effectively a 9.5 million unit line — and the rework cost lands somewhere.
For ISO 13485-certified manufacturers, quality-system controls are not optional additions; they are built into the process. What varies significantly between facilities is how well those controls are embedded into daily production versus reserved for audit events.
Checklist Item | Evidence to Request | Pass / Fail |
|---|---|---|
☐ Process validation records are current and cover the claimed production configurations | Validation reports (IQ/OQ/PQ) for each product family and packaging configuration you will order | |
☐ Acceptance criteria are defined per specification — not judgment-based | Written acceptance criteria per product type; first-pass yield targets | |
☐ In-process inspection controls are documented and not step-skippable under volume pressure | QC plan or control plan; in-process inspection records | |
☐ Non-conformance and CAPA systems are functional and responsive | CAPA log with open/closed status; average time to close in past 6 months | |
☐ ISO 13485 certification is current, scope covers the products you are sourcing, and the certifying body is accredited | Current ISO 13485 certificate with scope statement; accreditation body reference | |
☐ Traceability from raw material lot to finished-goods batch is documented | Sample traceability record (lot genealogy or batch record) |
When reviewing process validation records, pay particular attention to whether the validated configuration matches your order specification. A manufacturer may hold valid IQ/OQ/PQ documentation for a standard bordered dressing but have no validation records for a custom packaging format you require. This gap creates both regulatory exposure and lead-time uncertainty.
Section 5: Committed Capacity and Written Terms
The final step is converting verified capacity evidence into documented commercial terms. Verbal commitments from sales contacts have no operational value. What matters is the written capacity commitment — what the manufacturer is contractually willing to reserve for your volume without degrading service to other customers.
Checklist Item | Evidence to Request | Pass / Fail |
|---|---|---|
☐ Maximum sustainable weekly/monthly output is stated per SKU or product family | Written capacity commitment by SKU family; seasonal adjustment policy | |
☐ Lead-time commitments are written and conditions for exception are defined | Standard lead time; definitions of what triggers a lead-time extension | |
☐ Buffer-stock or vendor-managed inventory policy is documented | Buffer stock level and replenishment trigger; VMI terms if applicable | |
☐ Escalation procedure for capacity shortfalls is defined | Written escalation protocol: who contacts whom, timelines, remediation steps | |
☐ Change control notification timelines are specified — for process, packaging, and supplier changes | Change control SOP with notification period requirements | |
☐ Fill rate and on-time delivery performance data is available for the past 12 months | On-time delivery rate and fill rate by month; major exception explanations |
Pro Tip: Require that the capacity commitment be tied to the specific production lines you audited — not to total facility capacity. A manufacturer running 15 product lines may have strong aggregate numbers and persistent constraints on the lines relevant to your SKUs.
The SLK Medical Capacity Matrix: A Reference Model
Evaluating what verified documentation looks like in practice can be difficult without a reference point. SLK Medical — a wound care OEM manufacturer certified under ISO 13485, CE MDR, and FDA — publishes a capacity matrix that illustrates the kind of structured supply documentation distributors should be requesting from any supplier.
The matrix covers: stated monthly output (10 million dressings), production line configuration, facility specifications (10,000 m² facility with 100,000-level cleanroom), sterilization validation approach, and geographic expansion plans (a Cambodia manufacturing facility under renovation to add supply resilience). It is structured around the same three pillars this checklist addresses: output, uptime, and redundancy.
You can review SLK Medical’s OEM supply qualification guide for a detailed breakdown of how the capacity matrix is organized, what evidence accompanies each claim, and how the facility data connects to distributor SLA commitments. The silicone foam dressing OEM and private label buyer guide also provides a useful framework for how to structure your own supplier qualification conversation.
The reference is not presented here as the only way to format capacity documentation. It is one model that shows the checklist items above in a completed, evidence-backed format.
Scoring Your Supplier Assessment
Run through the five sections above and assign a status to each item:
Status | Definition |
|---|---|
✅ Passed | Evidence provided, verified, and satisfactory |
⚠️ Conditional | Evidence provided but requires clarification or follow-up |
❌ Failed | Evidence not provided, refused, or does not match the claim |
— Not applicable | Item is not relevant to this supplier or product scope |
Scoring guidance:
Any ❌ in Section 1 (OEE/Output), Section 3 (Redundancy), or Section 5 (Committed Terms): treat as a qualification hold until resolved. These are non-negotiable for multi-year supply relationships.
More than two ⚠️ items in Section 2 (Maintenance) or Section 4 (Quality): request a formal corrective action plan with owner names and dates before proceeding.
A supplier that refuses to share raw production data should be treated as a higher-risk partner regardless of their certification portfolio.
For distributors managing hospital tender commitments, the review above is not a one-time event. On-time delivery data, OEE trends, and safety stock levels should be reviewed quarterly. Most supply failures are preceded by warning signs in maintenance records and delivery data months before the actual disruption.
Next Steps
If you are currently evaluating a medical wound care OEM for a distribution partnership and want to understand how to align this checklist with a live supplier qualification conversation, you can request a capacity documentation package from SLK Medical — including production line data, certification copies, and a sample SLA framework.
For a broader overview of what makes a foam dressing OEM supply chain viable for international distribution, see how distributors vet a medical foam dressings OEM and the foam dressing supplier standards and certifications guide.
Frequently Asked Questions
What is a realistic OEE benchmark for a medical device manufacturer?
According to the 2025 Godlan OEE benchmark dataset, medical devices average 78.2% OEE across discrete manufacturing sectors — the highest of any tracked sector. Top-quartile performers exceed 85%. When evaluating a supplier, an OEE below 65% warrants careful investigation of maintenance practices and equipment age.
What is the difference between rated capacity and sustainable capacity?
Rated capacity is the theoretical maximum output under ideal, uninterrupted conditions. Sustainable capacity is what the plant repeatedly delivers after accounting for planned maintenance, changeovers, unplanned downtime, scrap, and regulatory holds. For planning purposes, use sustained actual capacity — typically supported by 8–12 weeks of native production records.
How many raw material sources should a qualified supplier maintain for silicone foam dressings?
For the two most critical materials — polyurethane foam and silicone adhesive systems — distributors should request at least two qualified suppliers on the approved supplier list. Single-source dependency on either material creates an unmanaged supply interruption risk regardless of how strong the manufacturer’s in-house operations are.
What written documentation should accompany a capacity commitment?
At a minimum: maximum sustainable output by SKU family, standard lead times and exception conditions, buffer stock policy, escalation procedure for shortfalls, and fill rate or on-time delivery history for the past 12 months. Capacity commitments tied to total facility output rather than to specific product lines should be treated with caution.
How often should distributor-supplier capacity reviews take place?
For strategic supply relationships — particularly those supporting hospital tender commitments — quarterly reviews of on-time delivery data, OEE trends, and safety stock levels are a reasonable baseline. Annual on-site or virtual audits provide a more complete view of facility condition and process discipline.
